Final results of a phase I radioimmunotherapy trial using 186Re-epratuzumab for the treatment of patients with non-Hodgkin's lymphoma

Clinical Cancer Research

Volumn 9, Issue 10 II, 2003, Pages

  Postema, Ernst J ^a   Raemaekers, John M M ^a   Oyen, Wim J G ^a   Boerman, Otto C ^a   Mandigers, Caroline M P W ^a   Goldenberg, David M ^b   Van Dongen, Guus A M S ^c   Corstens, Frans H M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CLEMASTINE; EPRATUZUMAB; EPRATUZUMAB RE 186; EPRATUZUMAB TC 99M; IPRATROPIUM BROMIDE; PREDNISOLONE; SALBUTAMOL; UNCLASSIFIED DRUG;

ADULT; AGED; AIRWAY OBSTRUCTION; ALLERGIC REACTION; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS HERPETIFORMIS; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG TOLERABILITY; DYSPNEA; FEMALE; FEVER; HERPES ZOSTER; HUMAN; LEUKOPENIA; MALE; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PHYSICAL EXAMINATION; PREMEDICATION; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SIDE EFFECT; SYNCOPE; TASTE DISORDER; THROMBOCYTOPENIA; THRUSH; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD22; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; CELL ADHESION MOLECULES; FEMALE; HUMANS; LECTINS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOMETRY; RHENIUM; TECHNETIUM; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 0141568082     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (19)

1. Postema, E. J., Boerman, O. C., Oyen, W. J. G., Raemaekers, J. M. M., and Corstens, F. H. M. Radioimmunotherapy of B-cell non-Hodgkin's lymphoma. Eur. J. Nucl. Med., 28: 1725-1735, 2001.
2. Goldenberg, D. M. The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy. Crit. Rev. Oncol. Hematol., 39: 195-201, 2001.
3. 90Y-labeled anti-CD20 monoclonal antibody. J. Nucl. Med., 43: 267-272, 2002.
4. Wiseman, G. A., White, C. A., Sparks, R. B., Erwin, W. D., Podoloff, D. A., Lamonica, D., Bartlett, N. L., Parker, J. A., Dunn, W. L., Spies, S. M., Belanger, R., Witzig, T. E., and Leigh, B. R. Biodistribution and dosimetry results from a Phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit. Rev. Oncol. Hematol., 39: 181-194, 2001.
5. Witzig, T. E., Gordon, L. I., Cabanillas, F., Czuczman, M. S., Emmanouilides, C., Joyce, R., Bartlett, N. L., Wiseman, G. A., Grillo-López, A. J., Multani, P., and White, C. A. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol., 20: 2453-2463, 2002.
6. Leung, S. O., Goldenberg, D. M., Dion, A. S., Pellegrini, M. C., Shevitz, J., Shih, L. B., and Hansen, H. J. Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/ lymphoma antibody, LL2. Mol. Immunol., 32: 1413-1427, 1995.
7. Press, O. W., Leonard, J. P., Coiffier, B., Levy, R., and Timmerman, J. Immunotherapy of non-Hodgkin's lymphomas. Hematology, 2001: 221-240, 2001.
8. Leonard, J. P., Coleman, M., Schuster, M. W., Chadbum, A., Ely, S., Yagan, N., Sharkey, R. M., Hansen, H. J., and Goldenberg, D. M. Epratuzumab, a new anti-CD22, humanized, monoclonal antibody for the therapy of non-Hodgkin's lymphoma (NHL): Phase I/II trial results. Blood, 94: 92a-93a, 1999.
9. Leonard, J. P., Coleman, M., Matthews, J. C., Fiore, J. M., Dosik, A., Shore, T., Kapushoc, H., Macri, M., Wegener, W. A., Cesano, A., and Goldenberg, D. M. Epratuzumab (anti-CD22) and rituximab (anti-CD20) combination immunotherapy for non-Hodgkin's lymphoma: preliminary response data. Proc. Am. Soc. Clin. Oncol., 21: 266a, 2002.
10. Visser, G. W. M., Gerretsen, M., Herscheid, J. D. M., Snow, G. B., and van Dongen, G. A. M. S. Labeling of monoclonal antibodies with rhenium-186 using the MAG3 chelate for radioimmunotherapy of cancer: a technical protocol. J. Nucl. Med., 34: 1953-1963, 1993.
11. Shen, S., DeNardo, G. L., Sgouros, G., O'Donnell, R. T., and DeNardo, S. J. Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. J. Nucl. Med., 40: 2102-2106, 1999.
12. Griffiths, G. L., Goldenberg, D. M., Diril, H., and Hansen, H. J. Technetium-99m, rhenium-186, and rhenium-188 direct-labeled antibodies. Cancer (Phila.), 73: 761-768, 1994.
13. Sharkey, R. M., Behr, T. M., Mattes, M. J., Stein, R., Griffiths, G. L., Shih, L. B., Hansen, H. J., Blumenthal, R. D., Dunn, R. M., Juweid, M. E., and Goldenberg, D. M. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22. Cancer Immunol. Immunother., 44: 179-188, 1997.
14. 88Y-labeled hLL2 (epratuzumab) in nude mice with CD22-positive lymphoma. Cancer Biother. Radiopharm., 18: in press, 2003.
15. Witzig, T. E. Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma. Cancer Chemother. Pharmacol., 48 (Suppl. 1): S91-S95, 2001.
16. Kaminski, M. S., Estes, J., Tuck, M., Mann, J., Fisher, S., Kison, P., Regan, D., Stagg, R., Kroll, S. M., Magnuson, D. E., and Wahl, R. L. Iodine I 131 tositumomab therapy for previously untreated follicular lymphoma. Proc. Am. Soc. Clin. Oncol., 19: 5a, 2000.
17. 90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. Clin. Cancer Res., 5 (Suppl.): 3292s-3303s, 1999.
18. Behr, T. M., Wörmann, B., Gramatzki, M., Riggert, J., Gratz, S., Béhé, M., Griesinger, F., Sharkey, R. M., Kolb, H-J., Hiddemann, W., Goldenberg, D. M., and Becker, W. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies. Clin. Cancer Res., 5 (Suppl.): 3304s-3314s, 1999.
19. Lindén, O., Cavallin-Ståhl, E., Strand, S. E., Hindorf, C., Tennvall, J., Stenberg, L., Ohlsson, T., and Darte, L. 90-Yttrium-epratuzumab in patients with B-cell lymphoma failing chemotherapy, using a dose fractionated schedule. Cancer Biother. Radiopharm., 17: 490, 2002.